Listing & Compliance Notices

Serina Therapeutics, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“November 22, 2022 we received a notification from the staff of the NYSE American (the “Exchange”) indicating that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide by increasing our stockholders equity to not less than $4,000,000. The Exchange staff will periodically review our adherence to the plan milestones. If we are not in compliance with the continued listing standards by May 17, 2023”

ALPINE 4 HOLDINGS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 22, 2022, the Company received a notice (the “November Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The November Notice indicated that under Nasdaq Listing Rules, the Company has 60 calendar days to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan, Nasdaq can grant an excepti”

Glucotrack, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 22, 2022, Nasdaq provided notice that pursuant to Nasdaq Listing Rule 5550(b)(1), GlucoTrack, Inc. (the “Company”) is required to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. Since its 10-Q for the period ended September 30, 2022 reported stockholders’ equity of $2,355,000, and as of November 22, 2022, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complies with the Rule. The Company has a 45-day period ending on January 6, 2023 to submit a plan of compli”

T2 Biosystems, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“November 22, 2022, the Company received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until May 22, 2023, to regain compliance. The letter states that the”

Adverum Biotechnologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“November 18, 2022, Adverum Biotechnologies, Inc. received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Adverum that for the last 30 consecutive business days the bid price of Adverum’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listing of Adverum’s common stock on Nasdaq. In accordance with listing rule 5810(c)(3)(A), Adverum has 180 calendar days, or until May 17, 2023, to re”

CONTRAFECT Corp received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of September 30, 2022 was approximately $(3.1) million. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market which currently trades”

Novo Integrated Sciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 21, 2022, Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”), received a notification letter (the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq. Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency co”

VIVEVE MEDICAL, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 18, 2022, Viveve Medical, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its quarterly report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission (the “Commission”) on November 10, 2022, the Company reported stockholders’ equity of $1,184,000, and, as a result, does not currentl”

Aceragen, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 22, 2022, Idera Pharmaceuticals, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s continued non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires maintenance of a minimum closing bid price of $1.00 per share (the “Bid Price Requirement”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request wil”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

“November 22, 2022, Eterna Therapeutics Inc. (the “ Company ”) received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s stockholders’ equity of approximately $8.8 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, fails to comply with the minimum $10.0 million stockholders’ equity requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(1)(A) (the “ Nasdaq Listing Rule ”). The Notice has no immediate effect on the listing of the Com”

Comera Life Sciences Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“November 18, 2022, Comera Life Sciences Holdings, Inc. (the “Company”) received a letter from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq listing rule 5550(b)(2). The notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Cap”

Global Star Acquisition Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“e required due date of November 14, 2022 and November 21, 2022, respectively. The Company also announced that it expected to receive a letter from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“ NASDAQ ”) stating that the Company is not in compliance with NASDAQ Listing Rule 5250(c)(1) (the “ Listing Rule ”) because it had not timely filed the Form 10-Q with the SEC. The Listing Rule requires listed companies to timely file all required periodic financial reports with the SEC. In connection with the foregoing, on November 22, 2022, the Company received such letter (the”

Talon 1 Acquisition Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 22, 2022, Talon 1 Acquisition Corp. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that because it was delinquent in filing its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”), it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice stated that the Company has”

USHG Acquisition Corp. received a nyse delisting notice notice regarding other (rules 802.01D).

“November 22, 2022, the New York Stock Exchange (the “NYSE”) notified the Company, and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants from the NYSE and that trading in the Company’s warrants would be suspended immediately, due to trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. As a result of the expected expiration of the warrants described above, the Company does not intend to appeal the NYSE’s determination. Forward-Looking Statements Some of the statements contained in this Current Report on Form 8-K m”

Tailwind International Acquisition Corp. received a nyse delisting notice notice regarding minimum bid price (rules 802.01D).

“per share (the “ Class A Ordinary Shares ”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “TWNI WS” (the “ Warrants ”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Class A Ordinary Shares and units will continue on the NYSE. The Warrants may be traded on the over-the-counter markets, or any other available market. Cautionary State”

Pontem Corp received a nyse deficiency notice notice regarding audit committee (rules 303A.07(a)).

“November 21, 2022, Pontem Corporation (the “Company”) notified the New York Stock Exchange (the “NYSE”) that the Company no longer had a majority of independent directors as required by Section 303A.01 of the NYSE Listed Company Manual and that the Company no longer had three directors on its Audit Committee as required by Section 303A.07(a) of the NYSE Listed Company Manual. The Company was not in compliance as the result of the resignation of Erik Olsson from the Company’s Board of Directors on November 10, 2022. On November 21, 2022, the Company received written notice from the NYSE that th”

Pontem Corp received a nyse deficiency notice notice regarding board independence (rules 303A.01).

“November 21, 2022, Pontem Corporation (the “Company”) notified the New York Stock Exchange (the “NYSE”) that the Company no longer had a majority of independent directors as required by Section 303A.01 of the NYSE Listed Company Manual and that the Company no longer had three directors on its Audit Committee as required by Section 303A.07(a) of the NYSE Listed Company Manual. The Company was not in compliance as the result of the resignation of Erik Olsson from the Company’s Board of Directors on November 10, 2022. On November 21, 2022, the Company received written notice from the NYSE that th”

EBET, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 29, 2021, EBET, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In accordanc”

Inspirato Inc received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“nspirato Incorporated (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Third Quarter Report”) with the Securities and Exchange Commission (the “SEC”) by the required due date. The Notice stated that, under Nasdaq rules, the Company”

Talkspace, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 18, 2022, Talkspace, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market (“ Nasdaq ”) notifying the Company that, for the previous 30 consecutive business days, the bid price of the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The Nasdaq letter has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance w”

Ayala Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C)).

“November 18, 2022, Ayala Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Requirement”). The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market and the Company’s common stock will continue to trade under the s”

SmileDirectClub, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 18, 2022, SmileDirectClub, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s Class A common stock (“Common Stock”), for the last 30 consecutive business days, the Common Stock was below the $1.00 minimum bid price requirement for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). As a result, the Company was notified by Nasdaq that it is not in compliance with the Minimum Bid Price Requirement (th”

Blue Star Foods Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 17, 2022, Blue Star Foods Corp. (the “Company”) received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requi”

Vinco Ventures, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 17, 2022, Vinco Ventures, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of the Company’s failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Form 10-Q”) with the United States Securities and Exchange Commission (the “SEC”) in a timely manner, which deadline was November 14, 2022. The Rule”

Fulgent Genetics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

“November 18, 2022, Fulgent Genetics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) to be comprised of a minimum of three independent directors. The Audit Committee is currently comprised of two independent directors and one vacancy. The Letter provides that the Company is eligible for a cure period in which to”

Entera Bio Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 21, 2022, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), received a notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s ordinary shares, par value of NIS 0.0000769 per share (the “ ordinary shares ”), fail to comply with the $1.00 minimum bid price requirement for continued listing on Nasdaq in accordance with Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the ordinary shares for the 30 consecutive business days prior to the date of the Notice. Pursuant to Nasdaq Listing”

Sintx Technologies, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(3)(A)(iii)).

“November 17, 2022, SINTX Technologies, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company’s bid price had closed below $0.10 per share for the preceding ten consecutive trading days, in contravention of Nasdaq Listing Rule 5810(3)(A)(iii) (the “$0.10 Rule”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). Today, the Company timely requested a hearing before the Panel, which request s”

XCel Brands, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“November 22, 2022, Xcel Brands, Inc. (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the minimum bid price per share for its common stock fell below $1.00 for a period of 30 consecutive business days. Therefore, the Company did not meet the minimum bid price requirement set forth in the Nasdaq Listing Rules. ​ The letters also state that pursuant to Nasdaq Listing Rules 5810(c)(3)(A), the Company will be provided 180 calendar days to regain compliance with the minimum bid price requirement, or until”

SEELOS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 21, 2022, Seelos Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until May 22, 2023, to regain compliance. The Notice s”

Kalera Public Ltd Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(3)(A)(iii)).

“November 21, 2022, Kalera Public Limited Company (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Staff had determined to delist the Company’s securities unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Staff’s determination was based upon the Company evidencing a closing bid price of less than $1 per share for the preceding thirty consecutive trading days, in contravention of Nasdaq Listing Rule 5550(a)(2), and less than $0.10 per share for the prece”

Altimar Acquisition Corp. III received a nyse delisting notice notice regarding other (rules 802.01D).

“November 21, 2022, the New York Stock Exchange (the “NYSE”) notified Altimar Acquisition Corp. III (the “Company”), and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants from the NYSE and that trading in the Company’s warrants would be suspended immediately, due to trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly auth”

Longview Acquisition Corp. II received a nyse noncompliance notice notice regarding audit committee (rules 303A.07).

“November 18, 2022, the Company received an official notice of non-compliance from the NYSE (the “NYSE Notice”). The NYSE Notice stated that the Company will need to correct the non-compliance as promptly as practicable. It is the intention of the Board to appoint a new independent director, duly qualified for service on each committee of the Board, as soon as practicable. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LONGVIEW ACQUISITION CORP. II”

Longview Acquisition Corp. II received a nyse noncompliance notice notice regarding board independence (rules 303A.01).

“November 18, 2022, the Company received an official notice of non-compliance from the NYSE (the “NYSE Notice”). The NYSE Notice stated that the Company will need to correct the non-compliance as promptly as practicable. It is the intention of the Board to appoint a new independent director, duly qualified for service on each committee of the Board, as soon as practicable. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LONGVIEW ACQUISITION CORP. II”

GoHealth, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“November 22, 2022, the Company received a written letter (the “Extension Notice”) from Nasdaq notifying the Company that Nasdaq has granted the Company an additional 180 calendar days, or until May 22, 2023 (the “Extension Period”), to regain compliance with the Minimum Bid Price Requirement. In addition, on November 16, 2022, Nasdaq notified the Company that it had approved the Company’s application to transfer its listing from Nasdaq’s Global Market tier to the Capital Market tier, which was a prerequisite to obtaining the Extension Period. This transfer was effective at the opening of busin”

Provident Bancorp, Inc. /MD/ received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 17, 2022, Provident Bancorp, Inc. (the “Company”) received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (the “Form 10-Q”), the Company is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq”

Singularity Future Technology Ltd. received a nasdaq deficiency notice notice regarding late filing.

“November 16, 2022, Singularity Future Technology Ltd. (the “Company”) received an additional staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), advising that it had not received the Company’s Form 10-Q for the quarterly period ended September 30, 2022, which served as an additional basis for delisting the Company’s securities and that the Nasdaq Hearings Panel (the “Panel”) will consider the additional deficiency in rendering a determination regarding the Company’s continued listing on The Nasdaq Capital Market. The C”

AYTU BIOPHARMA, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 22, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 22, 2023, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule under the Nasdaq Listing Rules, including enacting a reverse stock split. On October 5, 2022, the Company’s stockholders approved an amendment to its Cer”

UNISYS CORP received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“November 15, 2022, the Company received a notice (the “NYSE Notice”) from the New York Stock Exchange (the “NYSE”) indicating that, because the Company did not timely file the Quarterly Report, the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual, which requires that NYSE-listed companies timely file all periodic reports with the SEC. The NYSE Notice has no immediate effect on the listing of the Company’s common stock on the NYSE. The NYSE Notice informed the Company that, under NYSE rules, the Company has six months, until May 14, 2023, to file the Quarterly”

NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

“rate Compliance Department of the NYSE American Exchange (the “NYSE American”) indicating that as of November 15, 2022, the Partnership is not in compliance with the NYSE American’s standards for continued listing of the Partnership’s Depositary Receipts on the NYSE American as set forth in Section 1007 of the NYSE American Company Guide (the “Company Guide”). The Company failed to timely file (the “Filing Delinquency”) the Delayed Report. The NYSE American notification letter has no immediate effect on the listing or trading of the Partnership’s Depositary Receipts on the NYSE American, nor w”

Mercato Partners Acquisition Corp received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).

“November 17, 2022, Nasdaq issued a letter to the Company confirming the Company’s noncompliance with Nasdaq Listing Rule 5605 and informing the Company of the cure periods. The Company intends to appoint an additional independent director to the Board and the Audit Committee prior to the end of the cure periods. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mercato Partners Acquisition Corporation Date: November 21, 2022 By: /s/ Scott Klossner Na”

TuSimple Holdings Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 17, 2022, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Notice indicated that the Company can regain compliance with the Listing Rule at any time prior to January 16, 2023 by filing the Form 10-Q. If the Company fails to file the Form 10-Q by such date, the Company may submit a plan”

GELESIS HOLDINGS, INC. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“November 16, 2022, Gelesis Holdings, Inc. (the “Company”) received a notification letter (the “Notice”) from the New York Stock Exchange (the “NYSE”) advising that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE Listed Company Manual because its total market capitalization was less than $50 million over a 30 trading-day period and its stockholders’ equity was less than $50 million over a separate 30 trading-day period. The Company’s common stock will continue to be listed and traded on the NYSE during the Cure Period referred to below, subj”

Tuscan Holdings Corp. II received a nasdaq deficiency notice notice regarding other (rules IM-5101-2).

“July 11, 2022, the Company was not in compliance with Listing Rule IM-5101-2 (the “ Rule ”), which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of the registration statement filed in connection with its initial public offering. Since the Company’s registration statement became effective on July 11, 2019, it was required to complete an initial business combination by no later than July 11, 2022. The Company requested a hearing before an independent hearings panel, which request had stayed any suspension or d”

Tattooed Chef, Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“November 17, 2022, the Company filed the Form 10-Q with the SEC and received notice from Nasdaq that the Company had regained compliance with Rule 5250(c)(1).”

Tattooed Chef, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 16, 2022, Tattooed Chef, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”), due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022 (the “Form 10-Q”). On November 17, 2022, the Company filed the Form 10-Q with the SEC and received notice from Nasdaq that the Compa”

T Stamp Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 15, 2022, T Stamp Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of Class A Common Stock, par value $0.01 per share (the “Common Shares”), had closed below $1.00 per share of Common Stock, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 15, 2023, to regain compliance with the minimum bid price”

Bone Biologics Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 17, 2022, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the NASDAQ Stock Market LLC (“Nasdaq”) that the Company has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of”

Troika Media Group, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“November 17, 2022, the Company received a letter from Nasdaq granting the Company an additional 180 calendar days, or until May 15, 2023, to regain compliance with the Minimum Bid Price Rule. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Troika Media Group, Inc. (Registrant) Date: November 21, 2022 By: /s/ Erica Naidrich (Signature) Erica Naidrich Chief Financial Officer”

KVH INDUSTRIES INC DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 15, 2022, KVH received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, KVH is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Listing Rule ”), which requires timely filing of all required periodic financial reports with the SEC. The Notice indicated that, under Nasdaq Listing Rules, KVH has 60 calendar days to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts KVH’s plan, Nasdaq can grant an exception of up to 180 calendar days from the fili”

REPUBLIC FIRST BANCORP INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 14, 2022, Republic First Bancorp, Inc. (the “Company”) received notice from The NASDAQ Stock Market (“Nasdaq”) that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 with the Securities and Exchange Commission (the “Commission”), the Company does not comply with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all periodic reports with the Commission. As reported by the Company in its Current Report on Form 8-K, filed with”